{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Powder",
    "query": {
      "intervention": "Protein Powder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 353,
    "total_pages": 36,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Powder&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T06:48:02.087Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01561508",
      "title": "Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "gamma-amino-butyric acid",
          "type": "DRUG"
        },
        {
          "name": "Xylitol",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-12-24",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561508"
    },
    {
      "nct_id": "NCT02017249",
      "title": "Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "arginine in powder form",
          "type": "DRUG"
        },
        {
          "name": "Silica and cellulose placebo powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inova Health Care Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2014-03",
      "completion_date": "2015-10-06",
      "has_results": false,
      "last_update_posted_date": "2019-09-16",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02017249"
    },
    {
      "nct_id": "NCT04052698",
      "title": "Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Diseases"
      ],
      "interventions": [
        {
          "name": "Wilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2020-06-18",
      "completion_date": "2022-04-23",
      "has_results": true,
      "last_update_posted_date": "2023-10-25",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04052698"
    },
    {
      "nct_id": "NCT03821935",
      "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "Livmoniplimab",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2019-02-21",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 21,
      "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 16 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03821935"
    },
    {
      "nct_id": "NCT03554317",
      "title": "COMbination of Bipolar Androgen Therapy and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer",
        "Metastatic Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2018-09-05",
      "completion_date": "2023-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03554317"
    },
    {
      "nct_id": "NCT01490762",
      "title": "Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Technosphere Insulin Inhalation Powder using the Gen2C inhaler",
          "type": "DRUG"
        },
        {
          "name": "Regular Human Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 35,
      "start_date": "2011-12",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2012-09-07",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01490762"
    },
    {
      "nct_id": "NCT02932618",
      "title": "A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "Vonicog alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antihemophilic Factor (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 47,
      "start_date": "2017-11-06",
      "completion_date": "2026-04-17",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 16,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02932618"
    },
    {
      "nct_id": "NCT05482997",
      "title": "Athlete Whey Protein Sensitivity: Prevalence and Performance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Food Intolerance"
      ],
      "interventions": [
        {
          "name": "Whey Protein Concentrate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of the Incarnate Word",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2023-01-16",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-06-05",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05482997"
    },
    {
      "nct_id": "NCT01918657",
      "title": "Walnut Oral Immunotherapy for Tree Nut Allergy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "walnut powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonathan Spergel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Years to 21 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-02",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2014-09-10",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01918657"
    },
    {
      "nct_id": "NCT05515614",
      "title": "Targeted Nutrition for Moderate to Late Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Premature Birth",
        "Breastmilk Collection",
        "Postnatal Growth Restriction"
      ],
      "interventions": [
        {
          "name": "Targeted Fortification",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Enfamil Liquid Human Milk Fortifier",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 34,
      "start_date": "2022-08-17",
      "completion_date": "2023-05-11",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-09-08T06:48:02.087Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05515614"
    }
  ]
}